SON-1410 / Sonnet BioTherap - LARVOL DELTA

Sonnet BioTherapeutics Announces an Agreement with Janssen for the Evaluation of Three Sonnet Product Candidates (Issuer Direct) - "Sonnet BioTherapeutics Holdings...announced today a collaboration agreement with Janssen Biotech, Inc. (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, where in vitro and in vivo efficacy of SON-1010 (IL12-FHAB), SON-1210 (IL12-FHAB-IL15) and SON-1410 (IL18-FHAB-IL12) will be evaluated in combination with certain Janssen proprietary cell therapy assets. The agreement was facilitated by Johnson & Johnson Innovation. Sonnet shall supply the three referenced compounds for use in head-to-head studies. If successful and subject to provisions of the agreement, Sonnet could seek an expanded collaboration."

Licensing / partnership • Oncology

An innovative human platform for targeted delivery of bispecific interleukins to tumors (AACR 2022) - "Sonnet's bispecific drug candidates are constructed with IL-12 on the FHAB platform, and include IL12-FHAB-IL15, GMcsf-FHAB-IL12, and IL18-FHAB-IL12. This data points to the potential for changing immunologically “cold” tumors to clinically responsive “hot” ones.In conclusion, these studies demonstrated that while the powerful anti-tumor effects of IL-12 are evident in the monospecific IL12-FHAB, in the bispecific format IL-12 can synergize with other cytokines e.g., IL-18 and GM-CSF, resulting in superior anti-tumor activity when compared to their monospecific modalities. Ongoing in vitro and in vivo studies will involve bispecific IL-FHAB constructs used with various checkpoint inhibitors to further improve the immune stimulation and anti-tumor activities of novel combination therapies."

Melanoma • Oncology • Solid Tumor • CD8 • CSF2 • CXCL10 • CXCL9 • IL12A • IL15 • IL18

Sonnet BioTherapeutics Announces Preclinical Data Supporting Its Bispecific Interleukin Candidates at the American Association for Cancer Research (AACR) 2022 Annual Meeting (Yahoo Finance) - "Sonnet BioTherapeutics Holdings...announced today that data from preclinical studies of the company's proprietary Fully-Human Albumin Binding candidates, SON-1010, SON-1210, and SON-1410, will be presented in a poster session at the American Association for Cancer Research (AACR) Annual Meeting 2022....Sonnet's bispecific drug candidates are constructed with IL-12 on the FHAB platform (SON-1010) and include IL12-FHAB-IL15 (SON-1210) and IL18- FHAB-IL12 (SON-1410)....These studies demonstrate that beyond the powerful anti-tumor effects of IL-12 evident in the monospecific IL12-FHAB, in the bispecific format, IL-12 can synergize with other cytokines to produce superior anti-tumor activity."

Preclinical • Oncology

Sonnet BioTherapeutics Provides Fiscal Year 2022 First Quarter Business and Earnings Update (BioSpace) - "Sonnet provided the following corporate updates for the 2022 calendar year: Generating additional clinical product stability data for SON-1010 for the FDA in 1Q22; SON-1010 is on track for clinical study initiation in 2Q22...Completed R&D manufacturing for SON-1210 with initiation of a non-GLP pre-clinical toxicity study in non-human primateson track for 1H22. Completed sequence confirmation for SON-3015 and preparing for initial in vivo mice studies in 2H22. Lead optimization is underway to initiate CMC with cell line development for SON-1410 in 2Q22."

New molecule • New trial • Preclinical • Oncology

Sonnet BioTherapeutics Announces Abstract Accepted for Presentation in a Poster Session at the AACR 2022 Annual Meeting (Yahoo Finance) - "Sonnet BioTherapeutics Holdings...announced today that data from preclinical studies of the company's proprietary Fully Human Albumin Binding candidates, SON-1010, SON-1210, and SON-1410, will be presented at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2022, to be held April 8-13, in New Orleans, Louisiana."

Preclinical • Oncology

Sonnet Announces Successful Completion of the Discovery Phase for Its Next Preclinical Pipeline Candidate (SON-1410) (Yahoo Finance) - "Sonnet BioTherapeutics Holdings...announced today that it has selected a novel development candidate after completing comparative studies in a mouse melanoma model. The candidate represents Sonnet's second bispecific compound integrating Interleukin 12 (IL-12) with the company's Fully Human Albumin Binding (FHAB) platform. The target indications for SON-1410 will be melanoma and renal cancers."

Pipeline update • Melanoma • Oncology • Renal Cell Carcinoma